医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

USANA Health Sciences’China Subsidiary, BabyCare Ltd., Receives Approval for Eight Additional Direct Selling Licenses in Mainland China

2016年05月13日 AM02:15
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

USANA Health Sciences Inc. (NYSE: USNA), a global nutritional company, announced today that its China subsidiary, BabyCare Ltd., received approval from the Ministry of Commerce People’s Republic of China (MOFCOM) to expand direct selling activities in eight additional provinces/municipalities within China. The provinces/municipalities are Liaoning Province, Shandong Province, Shanxi Province, Sichuan Province, Guangdong Province, Dalian City, Qingdao City, and Shenzhen City. These additional licenses add to BabyCare’s existing direct selling licenses in the municipalities/provinces of Beijing, Jiangsu, Shanxi and Tianjin.

“We are pleased to have received these additional licenses in China, where we continue to expand the reach of our world-class products,” said Co-CEO Dave Wentz. “We remain committed to working with the Chinese government as we continue growing our business in this promising market.”

For more information about USANA’s products and company, visit USANA.com.

About USANA

USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia and Indonesia. More information on USANA can be found at http://www.usanahealthsciences.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160512006300/en/

CONTACT

USANA Health Sciences, Inc.
Investors Contact:
Patrique
Richards, 801-954-7961
Director of Investor Relations
investor.relations@us.usana.com
or
Media
Contact:
Dan Macuga, 801-954-7280
Chief Communications Officer
media(at)us.usana(dot)com
or
Media
Contact:
Ashley Collins, 801-954-7629
Executive Director of
PR, Social Media and Communications
media(at)us.usana(dot)com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Mitsui Chemicals Develops AIRYFA™The World’s First Flexible Nonwoven with High Strength
  • Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay
  • ドンペが中等度および重度の成人神経栄養性角膜炎患者の治療薬としてのOxervate®(Cenegermin点眼薬)に対するCHMPの肯定的意見を欧州で受領
  • Takeda Showcases Broadened Oncology Portfolio Through Data Presentations at Upcoming Medical Meetings
  • GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Japan